Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
167 hedge funds and large institutions have $1.09B invested in Aerie Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 77 increasing their positions, 31 reducing their positions, and 40 closing their positions.
148% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 31
120% more call options, than puts
Call options by funds: $16.9M | Put options by funds: $7.68M
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
0% more funds holding
Funds holding: 167 → 167 (0)
24% less capital invested
Capital invested by funds: $1.43B → $1.09B (-$339M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$41.9M |
| 2 |
DM
Deerfield Management
New York
|
+$35.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.4M |
| 4 |
LCS
Levin Capital Strategies
New York
|
+$22.2M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$44.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$30M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$27.5M |
| 4 |
Jennison Associates
New York
|
-$17.6M |
| 5 |
Neuberger Berman Group
New York
|
-$16.3M |
AERI Hedge Fund Activity: Q3 2019 in Review
167 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2019, worth a combined $1.09B — down 24% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AERI positions and 40 closed out — a net gain of 1 holder — while 77 added to existing stakes and 31 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $41.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $44.5M sold.
- 167 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $1.09B of Aerie Pharmaceuticals stock for Q3 2019, down 24% quarter-over-quarter.
- 41 funds opened new Aerie Pharmaceuticals positions in Q3 2019 and 40 closed out, a net change of +1 holder.
- The largest Aerie Pharmaceuticals buyer in Q3 2019 was PFM Health Sciences, an estimated $41.9M added.
- The largest Aerie Pharmaceuticals seller in Q3 2019 was Consonance Capital Management, an estimated $44.5M sold.
Based on aggregated 13F filings for Q3 2019.